Biotech | April 03, 2026
Nearly 40 industry groups unite to push for EU Biotech Act II
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
This marks a meaningful step in the company's continued expansion in the region
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Subscribe To Our Newsletter & Stay Updated
